Preliminary report published by Ulster University

RNS Number : 9696A

Omega Diagnostics Group PLC

02 October 2020

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Preliminary report published by Ulster University

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of the preliminary report of an independent evaluation of Abc-19^TM by Ulster University.

The independent report compares three commercially available immunoassays to evaluate performance metrics for the  AbC-19^TM lateral flow test, which is developed by the UK-RTC. The report notes the lack of a well-accepted gold standard assay against which to measure any newly developed immunoassay designed to detect antibodies to SARS-CoV-2.

To overcome these challenges, a 'pseudo gold standard' system was established against which to analyse the sensitivity and specificity of each of the three commercially available immunoassays using a well characterised serology sample set to evaluate performance metrics for the AbC-19^TM test. Using the 'pseudo gold standard' system the report concludes that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).

A link to the preliminary report can be found here:

https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1

Contacts: 

Omega Diagnostics Group PLC	Tel: [phone]
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

NRAEAEEAEDFEFFA